Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring
Status:
Withdrawn
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The overall goal of this study is to improve cardiovascular outcomes in transplant
recipients. The current standard immunosuppressive regimen in kidney transplant recipients
depends on a higher exposure to the Calcineurin Inhibitor (CNI), and often a less than
optimal dosage the of mycophenolic acid (MPA) derivative. The premise of this study is to
investigate the effects of reversing this paradigm. More specifically, the effect of using
maximum MPA dosages (in the form of enteric-coated mycophenolate sodium [EC-MPS] or
Myfortic®) along with judicious CNI exposure (cyclosporine/Neoral®) will be investigated.